Integrating genomics across drug discovery and development

Toxicology Letters

Volumn 186, Issue 1, 2009, Pages 9-12

  Debouck, Christine ^a  

^a Ardennes Biosciences LLC   (United States)

Author keywords

Biomarkers; Compound optimization; Disease mechanism; Genomics; Pharmacogenetics; Target validation

Indexed keywords

ARTICLE; BIOINFORMATICS; DNA SEQUENCE; DRUG RESEARCH; GENE SEQUENCE; GENETIC ANALYSIS; GENOMICS; HUMAN GENOME; PRIORITY JOURNAL; RNA SEQUENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTOMICS;

ANIMALS; BIOMEDICAL RESEARCH; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; DRUG INDUSTRY; EARLY DIAGNOSIS; GENOME, HUMAN; GENOMICS; HUMAN GENOME PROJECT; HUMANS; PHARMACOGENETICS;

EID: 61349117380     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2008.09.011     Document Type: Article

References (43)

1. Aitman T.J., Critser J.K., Cupper E., Dominiczak A., Fernandez-Suarez X., Flint J., Gauguier D., Geurts A.M., Gould M., Harris P.C., Holmdahl R., Hubner N., Izsvák Z., Jacob H.J., Kuramoto T., Kwitek A.E., Marrone A., Mashimo T., Moreno C., Mullins J., Mullins L., Olsson T., Pravenec M., Riley L., Saar K., Serikawa T., Shull J.D., Szpirer C., Twigger S.N., Voigt B., and Worley K. Progress and prospects in rat genetics: a community view. Nat. Genet. 40 (2008) 516-522
2. Altar C.A. The biomarkers consortium: on the critical path of drug discovery. Clin. Pharmacol. Ther. 83 (2008) 361-364
3. Amaral P.P., Dinger M.E., Mercer T.R., and Mattick J.S. The eukaryotic genome as an RNA machine. Science 319 (2008) 1787-1789
4. Bernstein B.E., Meissner A., and Lander E.S. The mammalian epigenome. Cell 128 (2007) 669-681
5. Blow N. RNAi technologies: a screen whose time has arrived. Nat. Methods 5 (2008) 361-368
6. Blow N. Structural genomics: inside a protein structure initiative center. Nat. Methods 5 (2008) 203-207
7. Buck W.R., Waring J.F., and Blomme E.A. Use of traditional end points and gene dysregulation to understand mechanisms of toxicity: toxicogenomics in mechanistic toxicology. Methods Mol. Biol. 460 (2008) 23-44
8. Burczynski M.E., and Dorner A.J. Transcriptional profiling of peripheral blood cells in clinical pharmacogenomic studies. Pharmacogenomics 7 (2006) 187-202
9. Bushel P.R., Heinloth A.N., Huang L., Chou J.W., Boorman G.A., Malarkey D.E., Houle C.D., Ward S.M., Wilson R.E., Fannin R.D., Russo M.W., Watkins P.B., Tennant R.W., and Paules R.S. Blood gene expression signatures predict exposure levels. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 18211-18216
10. Croce. Oncogenes and cancer. N. Engl. J. Med. 358 (2008) 502-511
11. Cutler P., Akuffo E.L., Bodnar W.M., Briggs D.M., Davis J.B., Debouck C.M., Fox S.M., Gibson R.A., Gormley D.A., Holbrook J.D., Hunter A.J., Kinsey E.E., Prinjha R., Richardson J.C., Roses A.D., Smith M.A., Tsokanas N., Willé D.R., Wu W., Yates J.W., and Gloger I.S. Proteomic identification and early validation of complement 1 inhibitor and pigment epithelium-derived factor: two novel biomarkers of Alzheimer's disease in human plasma. Proteomics Clin. Appl. 2 (2008) 467-477
12. DeKosky S.T., and Marek K. Looking backward to move forward: early detection of neurodegenerative disorders. Science 302 (2003) 830-834
13. Ellinger-Ziegelbauer H., Gmuender H., Bandenburg A., and Ahr H.J. Prediction of a carcinogenic potential of rat hepatocarcinogens using toxicogenomics analysis of short-term in vivo studies. Mutat. Res. 637 (2008) 23-39
14. Guido R.V., Oliva G., and Andricopulo A.D. Virtual screening and its integration with modern drug design technologies. Curr. Med. Chem. 15 (2008) 37-46
15. Hanash S.M., Pitteri S.J., and Faca V.M. Mining the plasma proteome for cancer biomarkers. Nature 452 (2008) 571-579
16. Holden A.L. The SNP consortium: summary of a private consortium effort to develop an applied map of the human genome. Biotechniques 32 (2002) S22-S26
17. Hudder A., and Novak R.F. miRNAs: effectors of environmental influences on gene expression and disease. Toxicol. Sci. 103 (2008) 228-240
18. International HapMap Consortium. A haplotype map of the human genome. Nature 437 (2005) 1299-1320
19. International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 409 (2001) 860-921
20. International Mouse Knockout Consortium, Collins F.S., Rossant J., and Wurst W. A mouse for all reasons. Cell 128 (2007) 9-13
21. Khoury M.J., Gwinn M., Yoon P.W., Dowling N., Moore C.A., and Bradley L. The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention?. Genet. Med. 9 (2007) 665-674
22. Kola I. The state of innovation in drug development. Clin. Pharmacol. Ther. 83 (2008) 227-230
23. Lesko L.J. Paving the critical path: how can clinical pharmacology help achieve the vision?. Clin. Pharmacol. Ther. 81 (2007) 170-177
24. Lin J., and Qian J. Systems biology approach to integrative comparative genomics. Expert Rev. Proteomics 4 (2007) 107-119
25. Lum P.Y., He Y.D., Slatter J.G., Waring J.F., Zelinsky N., Cavet G., Dai X., Fong O., Gum R., Jin L., Adamson G.E., Roberts C.J., Olsen D.B., Hazuda D.J., and Ulrich R.G. Gene expression profiling of rat liver reveals a mechanistic basis for ritonavir-induced hyperlipidemia. Genomics 90 (2007) 464-473
26. Manolio T.A., Brooks L.D., and Collins F.S. A HapMap harvest of insights into the genetics of common disease. J. Clin. Invest. 118 (2008) 1590-1605
27. Marchetti S., and Schellens J.H. The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials. Br. J. Cancer 97 (2007) 577-581
28. Mathivanan S., and Pandey A. Human proteinpedia as a resource for clinical proteomics. Mol. Cell. Proteomics 7 (2008) 2038-2047
29. Mattingly C.J., Rosenstein M.C., Davis A.P., Colby G.T., Forrest Jr. J.N., and Boyer J.L. The comparative toxicogenomics database: a cross-species resource for building chemical-gene interaction networks. Toxicol. Sci. 92 (2006) 587-595
30. Mons B., Ashburner M., Chichester C., van Mulligen E., Weeber M., den Dunnen J., van Ommen G.-J., Musen M., Cockerill M., Hermjakob H., Mons A., Packer A., Pacheco R., Lewis S., Berkeley A., Melton W., Barris N., Wales J., Meijssen G., Moeller E., Roes P.J., Borner K., and Bairoch A. Calling on a million minds for community annotation in WikiProteins. Genome Biol. 9 (2008) R89.1-R89.15
31. Nevins J.R., and Potti A. Mining gene expression profiles: expression signatures as cancer phenotypes. Nat. Rev. Genet. 8 (2007) 601-609
32. Payne D.J., Gwynn M.N., Holmes D.J., and Pompliano D.L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6 (2007) 29-40
33. Seguin B., Hardy B.-J., Singer P.A., and Daar A.S. Genomic medicine and developing countries: creating a room of their own. Nat. Rev. Genet. 9 (2008) 487-493
34. Shendure J. The beginning of the end for microarrays?. Nat. Methods 5 (2008) 585-587
35. Tan S.-L., Ganji G., Paeper B., Proll S., and Katze M. Systems biology and the host response to viral infection. Nat. Biotechnol. 25 (2007) 1383-1389
36. Tan K., Tegner J., and Ravasi T. Integrated approaches to uncovering transcription regulatory networks in mammalian cells. Genomics 91 (2008) 219-231
37. Van't Veer L.J., and Bernards R. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 452 (2008) 564-570
38. Waters M., Stasiewicz S., Merrick B.A., Tomer K., Bushel P., Paules R., Stegman N., Nehls G., Yost K.J., Johnson C.H., Gustafson S.F., Xirasagar S., Xiao N., Huang C.-C., Boyer P., Chan D.D., Pan Q., Gong H., Taylor J., Choi D., Rashid A., Ahmed A., Howle R., Selkirk J., Tennant R., and Fostel J. CEBSchemical effects in biological systems: a public data repository integrating study design and toxicity data with microarray and proteomics data. Nucleic Acids Res. 36 (2008) D892-D900
39. Weissleder R., and Pittet M.J. Imaging in the era of molecular oncology. Nature 452 (2008) 580-589
40. Wilke R.A., Lin D.W., Roden D.M., Watkins P.B., Flockhart D., Zineh I., Giacomini K.M., and Krauss R.M. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat. Rev. Drug Discov. 6 (2007) 904-916
41. Wilson S., Bergsma D.J., Chambers J.K., Muir A.I., Fantom K.G., Ellis C., Murdock P.R., Herrity N.C., and Stadel J.M. Orphan G-protein-coupled receptors: the next generation of drug targets?. Br. J. Pharmacol. 125 (1998) 1387-1392
42. Woodcock J., and Woosley R. The FDA critical path initiative and its influence on new drug development. Annu. Rev. Med. 59 (2008) 1-12
43. Zambrowicz B.P., and Sands A.T. Knockouts model the 100 best-selling drugs-will they model the next 100?. Nat. Rev. Drug Discov. 2 (2003) 38-51